Alnylam Pharmaceuticals
ALNY
#585
Rank
€31.31 B
Marketcap
243,94 €
Share price
1.90%
Change (1 day)
40.75%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2023 (TTM): -3,77 €

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is -3,71 €. In 2022 the company made an earnings per share (EPS) of -8,38 € a decrease over its 2021 EPS that were of -6,50 €.

EPS history for Alnylam Pharmaceuticals from 2003 to 2023

Annual EPS

Year EPS Change
2023 (TTM)-3,77 €-55.09%
2022-8,38 €29.03%
2021-6,50 €-3.36%
2020-6,72 €-8.48%
2019-7,35 €7.67%
2018-6,82 €39.74%
2017-4,88 €12.94%
2016-4,32 €38.84%
2015-3,11 €-32.88%
2014-4,64 €259.44%
2013-1,29 €-31.25%
2012-1,88 €52.94%
2011-1,23 €30.77%
2010-0,94 €-8.77%
2009-1,03 €78.13%
2008-0,58 €-70.78%
2007-1,98 €99.09%
2006-0,99 €-43.88%
2005-1,77 €-82.33%
2004-10,01 €-59.23%
2003-24,55 €

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
-1,53 €-58.64%🇺🇸 USA
33,71 €-1,009.00%🇺🇸 USA
-7,07 € 90.51%🇺🇸 USA
-0,24 €-93.43%🇺🇸 USA
-1,53 €-58.88%🇺🇸 USA
3,37 €-191.00%🇨🇭 Switzerland
2,87 €-177.38%🇫🇷 France
-1,80 €-51.34%🇮🇱 Israel